Kirk G. Nielsen - 05 Feb 2026 Form 3 Insider Report for SpyGlass Pharma, Inc. (SGP)

Role: Director, 10%+ Owner
Signature: /s/ Brian Aukshunas, as Attorney-in-Fact
Issuer symbol: SGP
Transactions as of: 05 Feb 2026
Net transactions value: $0
Form type: 3
Filing time: 05 Feb 2026, 13:10:31 UTC
Previous filing: 05 Jun 2025
Next filing: 11 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Nielsen Kirk G.	Director, 10%+ Owner	C/O SPYGLASS PHARMA, INC., 27061 ALISO CREEK RD., SUITE 100, ALISO VIEJO	/s/ Brian Aukshunas, as Attorney-in-Fact	05 Feb 2026	0001523522

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Ownership	Footnotes
holding	SGP	Series B Preferred Stock	05 Feb 2026	Common Stock	1,690,230	See footnote	F1, F2
holding	SGP	Series C-1 Preferred Stock	05 Feb 2026	Common Stock	548,067	See footnote	F1, F2
holding	SGP	Series C-2 Preferred Stock	05 Feb 2026	Common Stock	548,067	See footnote	F1, F2
holding	SGP	Series D Preferred Stock	05 Feb 2026	Common Stock	359,255	See footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	All shares of the preferred stock, par value $0.00001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
F2	These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Content

All shares of the preferred stock, par value $0.00001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.

These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Remarks:

Exhibit 24 - Power of Attorney